Overview
AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer
and biodefense threats which has the potential to redefine vaccines and the role they play in medicine.
AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines,
which have shown excellent protection in multiple models for infectious disease and cancer. Since 1998, the
company has raised more than $133 million, with ~70% coming from corporate partner and grant funding, and has
advanced the alphavaccine platform system from the academic laboratory to human clinical trials, establishing
the technical, regulatory, and manufacturing foundation for commercializing alphavaccines.
The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and
collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical
data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune
responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell)
immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical
work with this vector platform.
The vaccine market is primed for dramatic growth and the AlphaVax vaccine technology will play a key role in an
expanding industry expected to reach $20 billion by 2015.
We are located in Research Triangle Park, North Carolina and employ over 70 staff in a state-of-the-art, 30,000-square-foot
research facility that includes Bio-Safety Level 2 and 3 (BSL-2/3) laboratories, and a 10,000-square-foot development facility.
Our technical capabilities encompass vector design and development, new product research, product and process development,
GMP manufacturing and technology transfer, quality assurance, and regulatory and clinical affairs. We also manage a GMP
clinical supply operation in a leased BSL-3 vaccine production facility in Lenoir, North Carolina.
AlphaVax began operations in 1998, is privately owned, and has been financed to date by an unusual mix of grant funding,
corporate partnership income, and private equity.
Read more about our financial profile.
Some of our key milestones and accomplishments include:
- A sound clinical safety and regulatory profile
- Phase 1 Trials completed for Influenza and HIV with positive results
- Phase 1 Trial for Cytomegalovirus (CMV) and Phase 1/2 Trial for colon cancer ongoing
- Established process and product development expertise
- In-house GMP clinical trial manufacturing capability
- Industry partnership in cancer
- Academic partnerships in tumor immunotherapy
- A product pipeline spanning over a dozen applications
- Peer-reviewed grant funding over $80 million
- Private equity and corporate investment over $53 million
- An extensive flow of new scientific improvements and proprietary know-how
- An experienced management team